HUMA Humacyte, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1818382 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY52.5%
TTM net income YoY-156.3%
TTM EPS YoY-66.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-475.1%
Operating margin-4,602.9%
Net margin-3,955.1%
FCF margin-3,697.0%
EBITDA margin-4,381.8%
Returns
ROE-1,423.6%
ROA-87.3%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets85.6%
Debt / equity2.04x
Current ratio3.34x
Interest coverage-10.97x
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-6.0%
Payout ratio—
Capex / revenue13.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.04M | $0 | — | — | — |
| Cost of revenue | $9.70M | $0 | — | — | — |
| Gross profit | -$7.66M | $0 | — | — | — |
| R&D expense | $69.30M | $88.60M | $76.55M | $63.26M | $61.34M |
| SG&A expense | $31.17M | $25.80M | $23.50M | $22.88M | $21.13M |
| Operating income | -$108.14M | -$114.40M | -$100.05M | -$84.58M | -$81.21M |
| Interest expense | $11.25M | $9.28M | $6.60M | $6.20M | $4.35M |
| Pretax income | -$40.83M | — | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$40.83M | -$148.70M | -$110.78M | -$11.96M | -$26.48M |
| EBITDA | -$102.81M | -$109.29M | -$94.39M | -$78.43M | -$75.03M |
| EPS (basic) | -0.26 | -1.26 | -1.07 | -0.12 | -0.66 |
| EPS (diluted) | -0.26 | -1.26 | -1.07 | -0.12 | -0.66 |
| Weighted avg. shares (diluted) | 158.16M | 118.48M | 103.42M | 103.05M | 39.97M |
| Balance sheet | |||||
| Cash & equivalents | $50.50M | $95.29M | $80.80M | $149.77M | $217.50M |
| Short-term investments | — | — | $0 | $2.11M | $8.00M |
| Receivables | $441,000 | $0 | $0 | $31,000 | $176,000 |
| Inventory | $13.59M | $0 | — | — | — |
| Current assets | $67.80M | $47.86M | $83.28M | $154.21M | $229.34M |
| PP&E, net | $18.54M | $23.06M | $26.79M | $30.04M | $35.03M |
| Total assets | $116.37M | $137.87M | $128.22M | $204.30M | $286.53M |
| Current liabilities | $18.37M | $19.95M | $18.44M | $19.58M | $11.05M |
| Long-term debt | $35.44M | $0 | — | — | $30.00M |
| Total debt | $35.44M | $0 | — | — | $30.00M |
| Total liabilities | $113.26M | $190.54M | $114.68M | $87.37M | $164.36M |
| Shareholders' equity | $3.11M | -$52.67M | $13.55M | $116.93M | $122.17M |
| Net debt | -$15.05M | -$95.29M | — | — | -$187.50M |
| Shares outstanding | 193.00M | 130.03M | 103.67M | 103.23M | 103.00M |
| Cash flow statement | |||||
| Operating cash flow | -$105.04M | -$98.12M | -$73.31M | -$71.13M | -$81.19M |
| Capital expenditure | $884,000 | $1.57M | $2.28M | $1.05M | $220,000 |
| Free cash flow | -$105.93M | -$99.69M | -$75.58M | -$72.18M | -$81.41M |
| Investing cash flow | -$884,000 | -$1.57M | -$173,000 | $4.84M | -$8.22M |
| Financing cash flow | $61.49M | $114.18M | $4.51M | -$1.45M | $266.98M |
| Depreciation & amortization | $5.33M | $5.10M | $5.66M | $6.15M | $6.18M |
| Stock-based compensation | $9.75M | $6.14M | $6.83M | $6.18M | $10.15M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.